HDAC9 and prostate carcinoma: These inhibitors have shown hyperacetylation of histones H‐3 and H‐4 in DU‐145 prostate cancer cells in a dose dependent manner and at much lower doses required by the parent molecule indicating that they are potent HDAC inhibitors.26